Log in to your Inderes Free account to see all free content on this page.
Lundbeck
41.54 DKK +1.32%2 investors are following this company
Lundbeck is a pharmaceutical company. The greatest focus is found in research on psychiatric and neurotic disorders, which includes the treatment of depression, schizophrenia, Alzheimer's and Parkinson's syndrome. The company conducts research, development and distribution of medicines where the customer base can be found on a global level. The company was originally founded in 1915 and has its headquarters in Valby.
Revenue
-
EBIT %
-
P/E
17.98
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Copenhagen
HLUN B
Daily low / high price
40.68 / 41.6
DKK
Market cap
41.36B DKK
Turnover
10.21M DKK
Volume
247K
Financial calendar
Interim report
21.08.2024
Interim report
13.11.2024
ShowingAll content types
H. Lundbeck A/S: Lundbeck broadens focus on neurohormonal dysfunctions with new Cushing's disease trial
H. Lundbeck A/S: Lundbeck presents innovative first in human trial design of Lu AG13909 for potential treatment of congenital adrenal hyperplasia
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio